Myriad Genetics (MYGN) Stock Forecast, Price Target & Predictions
MYGN Stock Forecast
Myriad Genetics stock forecast is as follows: an average price target of $29.00 (represents a 90.54% upside from MYGN’s last price of $15.22) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.
MYGN Price Target
The average price target for Myriad Genetics (MYGN) is $29.00 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $22.00. This represents a potential 90.54% upside from MYGN's last price of $15.22.
MYGN Analyst Ratings
According to 13 Wall Street analysts, Myriad Genetics's rating consensus is 'Hold'. The analyst rating breakdown for MYGN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (30.77%), 9 'Hold' (69.23%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Myriad Genetics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | Sung Ji Nam | Scotiabank | $34.00 | $24.67 | 37.82% | 123.39% |
| Sep 19, 2024 | Tejas Savant | Morgan Stanley | $32.00 | $28.47 | 12.40% | 110.25% |
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $35.00 | $27.50 | 27.27% | 129.96% |
| Aug 07, 2024 | Subbu Nambi | Guggenheim | $29.00 | $25.96 | 11.71% | 90.54% |
| Jun 26, 2024 | Sung Ji Nam | Scotiabank | $29.00 | $24.62 | 17.79% | 90.54% |
| May 13, 2024 | Jon Peterson | Piper Sandler | $28.00 | $25.07 | 11.69% | 83.97% |
| Dec 21, 2023 | David Westenberg | Piper Sandler | $23.00 | $20.49 | 12.25% | 51.12% |
| Oct 05, 2022 | Mason Carrico | Stephens | $22.00 | $20.82 | 5.67% | 44.55% |
| Apr 19, 2022 | - | Goldman Sachs | $23.00 | $23.03 | -0.13% | 51.12% |
The latest Myriad Genetics stock forecast, released on Oct 14, 2024 by Sung Ji Nam from Scotiabank, set a price target of $34.00, which represents a 37.82% increase from the stock price at the time of the forecast ($24.67), and a 123.39% increase from MYGN last price ($15.22).
Myriad Genetics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 7 |
| Avg Price Target | - | $33.67 | $30.00 |
| Last Closing Price | $15.22 | $15.22 | $15.22 |
| Upside/Downside | -100.00% | 121.22% | 97.11% |
In the current month, the average price target of Myriad Genetics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Myriad Genetics's last price of $15.22. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Sep 19, 2024 | Morgan Stanley | - | Equal-Weight | Initialise |
| Aug 27, 2024 | Wells Fargo | - | Overweight | Initialise |
| Aug 13, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Aug 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 07, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 07, 2024 | Guggenheim | Buy | Buy | Hold |
| Jun 26, 2024 | Scotiabank | Outperform | Sector Outperform | Initialise |
| Jun 26, 2024 | Scotiabank | - | Outperform | Initialise |
| Jun 03, 2024 | Jefferies | - | Underperform | Downgrade |
Myriad Genetics's last stock rating was published by Scotiabank on Oct 14, 2024. The company gave MYGN a "Sector Outperform" rating, the same as its previous rate.
Myriad Genetics Financial Forecast
Myriad Genetics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $191.90M | - | $181.20M | $177.80M | $156.40M | $179.30M | $164.90M | $160.80M | $167.30M | $189.40M | $173.10M | $154.60M | $145.20M | $93.20M | $164.00M | $195.10M | $186.30M |
| Avg Forecast | $249.02M | $242.63M | $241.01M | $230.95M | $227.38M | $220.36M | $220.97M | $212.71M | $213.51M | $210.76M | $206.44M | $193.51M | $194.80M | $182.32M | $187.16M | $171.49M | $169.47M | $170.07M | $170.96M | $156.67M | $162.96M | $165.04M | $162.54M | $154.42M | $93.89M | $167.38M | $209.66M | $202.32M | $221.64M | $217.77M |
| High Forecast | $256.68M | $250.09M | $248.42M | $238.05M | $234.37M | $227.13M | $227.76M | $223.96M | $217.22M | $210.85M | $206.44M | $193.63M | $195.47M | $183.87M | $192.91M | $176.77M | $174.68M | $170.07M | $170.96M | $156.67M | $162.96M | $165.04M | $162.54M | $154.42M | $93.89M | $167.38M | $209.66M | $202.32M | $221.64M | $217.77M |
| Low Forecast | $241.58M | $235.38M | $233.81M | $224.05M | $220.58M | $213.77M | $214.37M | $203.00M | $209.88M | $210.66M | $206.44M | $193.38M | $193.36M | $180.77M | $181.56M | $166.37M | $164.41M | $170.07M | $170.96M | $156.67M | $162.96M | $165.04M | $162.54M | $154.42M | $93.89M | $167.38M | $209.66M | $202.32M | $221.64M | $217.77M |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | - | 1.06% | 1.05% | 0.92% | 1.05% | 1.05% | 0.99% | 1.01% | 1.17% | 1.12% | 1.65% | 0.87% | 0.44% | 0.81% | 0.88% | 0.86% |
Myriad Genetics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $194.80M, with a low forecast of $193.36M, and a high forecast of $195.47M. MYGN's average Quarter revenue forecast represents a 1.51% increase compared to the company's last Quarter revenue of $191.90M (Sep 23).
Myriad Genetics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-46.10M | $-297.20M | $-32.70M | $-31.30M | $-30.30M | $-4.40M | $-1.80M | $-29.70M | $55.10M | $15.10M | $-28.20M | $-34.70M | $-23.10M | $-37.60M | $-110.90M | $9.30M | $-1.20M |
| Avg Forecast | $-4.92M | $-4.79M | $-4.76M | $-4.56M | $-4.49M | $-4.35M | $-4.36M | $-4.20M | $-4.22M | $-4.16M | $-4.08M | $-21.39M | $-3.85M | $-3.60M | $-3.70M | $-19.45M | $-32.67M | $-3.36M | $-3.38M | $-17.68M | $-3.22M | $-3.26M | $-3.21M | $-39.88M | $-1.85M | $-3.31M | $-4.14M | $-998.10M | $-4.38M | $-4.30M |
| High Forecast | $-4.77M | $-4.65M | $-4.62M | $-4.42M | $-4.36M | $-4.22M | $-4.23M | $-4.01M | $-4.14M | $-4.16M | $-4.08M | $-17.11M | $-3.82M | $-3.57M | $-3.59M | $-15.56M | $-26.14M | $-3.36M | $-3.38M | $-14.14M | $-3.22M | $-3.26M | $-3.21M | $-31.91M | $-1.85M | $-3.31M | $-4.14M | $-798.48M | $-4.38M | $-4.30M |
| Low Forecast | $-5.07M | $-4.94M | $-4.91M | $-4.70M | $-4.63M | $-4.49M | $-4.50M | $-4.42M | $-4.29M | $-4.16M | $-4.08M | $-25.67M | $-3.86M | $-3.63M | $-3.81M | $-23.34M | $-39.20M | $-3.36M | $-3.38M | $-21.21M | $-3.22M | $-3.26M | $-3.21M | $-47.86M | $-1.85M | $-3.31M | $-4.14M | $-1.20B | $-4.38M | $-4.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.80% | 80.41% | 1.68% | 0.96% | 9.02% | 1.30% | 0.10% | 9.23% | -16.91% | -4.70% | 0.71% | 18.71% | 6.99% | 9.08% | 0.11% | -2.12% | 0.28% |
5 analysts predict MYGN's average Quarter EBITDA for Dec 21 to be $-3.22M, with a high of $-3.22M and a low of $-3.22M. This is -105.84% lower than Myriad Genetics's previous annual EBITDA (Sep 21) of $55.10M.
Myriad Genetics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-61.30M | $-116.10M | $-54.70M | $-42.30M | $-35.10M | $-14.10M | $-20.50M | $-7.60M | $24.60M | $-4.70M | $-39.50M | $-44.20M | $-15.20M | $-55.40M | $-115.20M | $-8.30M | $-20.60M |
| Avg Forecast | $8.42M | $6.98M | $6.91M | $5.02M | $5.36M | $3.17M | $1.75M | $77.48K | $2.22M | $1.53M | $-955.53K | $-35.08M | $1.16M | $-6.19M | $-6.64M | $-31.89M | $-8.36M | $-3.28M | $2.05M | $-28.99M | $-1.94M | $-1.46M | $-8.28M | $-55.86M | $-38.13M | $614.25K | $25.08M | $-1.04B | $38.19M | $35.51M |
| High Forecast | $8.76M | $7.26M | $7.18M | $5.22M | $5.57M | $3.29M | $1.82M | $232.43K | $2.31M | $1.57M | $-918.41K | $-28.07M | $1.21M | $-5.95M | $-6.38M | $-25.51M | $-6.69M | $-3.28M | $2.05M | $-23.19M | $-1.94M | $-1.46M | $-8.28M | $-44.69M | $-38.13M | $614.25K | $25.08M | $-829.44M | $38.19M | $35.51M |
| Low Forecast | $8.09M | $6.71M | $6.64M | $4.82M | $5.15M | $3.04M | $1.68M | $-154.95K | $1.48M | $1.50M | $-993.71K | $-42.10M | $580.14K | $-6.44M | $-6.91M | $-38.27M | $-10.03M | $-3.28M | $2.05M | $-34.79M | $-1.94M | $-1.46M | $-8.28M | $-67.04M | $-38.13M | $614.25K | $25.08M | $-1.24B | $38.19M | $35.51M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.91% | 17.48% | 1.72% | 5.06% | 10.71% | -6.89% | 0.71% | 3.91% | -16.90% | 0.57% | 0.71% | 1.16% | -24.75% | -2.21% | 0.11% | -0.22% | -0.58% |
Myriad Genetics's average Quarter net income forecast for Dec 21 is $-1.94M, with a range of $-1.94M to $-1.94M. MYGN's average Quarter net income forecast represents a -107.89% decrease compared to the company's last Quarter net income of $24.60M (Sep 21).
Myriad Genetics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $170.40M | $140.70M | $151.70M | $146.50M | $130.50M | $127.10M | $110.60M | $139.30M | $180.20M | $134.80M | $145.50M | $132.90M | $124.10M | $107.40M | $132.90M | $135.60M | $135.50M |
| Avg Forecast | $190.83M | $185.93M | $184.69M | $176.98M | $174.24M | $168.86M | $169.33M | $163.00M | $163.61M | $161.50M | $158.19M | $189.27M | $149.28M | $139.71M | $143.42M | $131.42M | $85.03M | $130.32M | $131.00M | $156.42M | $124.88M | $126.47M | $124.56M | $118.33M | $71.95M | $128.27M | $160.67M | $155.03M | $169.84M | $166.88M |
| High Forecast | $196.69M | $191.65M | $190.36M | $182.42M | $179.60M | $174.05M | $174.53M | $171.62M | $166.45M | $161.57M | $158.19M | $227.12M | $149.79M | $140.90M | $147.83M | $135.46M | $102.04M | $130.32M | $131.00M | $187.70M | $124.88M | $126.47M | $124.56M | $118.33M | $71.95M | $128.27M | $160.67M | $155.03M | $169.84M | $166.88M |
| Low Forecast | $185.12M | $180.38M | $179.17M | $171.69M | $169.03M | $163.81M | $164.27M | $155.56M | $160.83M | $161.43M | $158.19M | $151.41M | $148.17M | $138.53M | $139.13M | $127.49M | $68.02M | $130.32M | $131.00M | $125.14M | $124.88M | $126.47M | $124.56M | $118.33M | $71.95M | $128.27M | $160.67M | $155.03M | $169.84M | $166.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.22% | 0.98% | 1.15% | 1.72% | 1.00% | 0.97% | 0.71% | 1.12% | 1.42% | 1.08% | 1.23% | 1.85% | 0.97% | 0.67% | 0.86% | 0.80% | 0.81% |
Myriad Genetics's average Quarter SG&A projection for Dec 23 is $149.28M, based on 8 Wall Street analysts, with a range of $148.17M to $149.79M. The forecast indicates a -12.40% fall compared to MYGN last annual SG&A of $170.40M (Sep 23).
Myriad Genetics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | $-0.18 | $-0.26 | $-0.10 | $0.31 | $-0.06 | $-0.52 | $-0.59 | $-0.20 | $-0.74 | $-1.55 | $-0.11 | $-0.28 |
| Avg Forecast | $0.10 | $0.09 | $0.08 | $0.06 | $0.07 | $0.04 | $0.02 | - | $0.03 | $0.02 | $-0.01 | $-0.10 | $0.01 | $-0.08 | $-0.08 | $-0.19 | $-0.16 | $-0.04 | $0.03 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.47 | $0.01 | $0.31 | $0.31 | $0.47 | $0.43 |
| High Forecast | $0.11 | $0.09 | $0.09 | $0.06 | $0.07 | $0.04 | $0.02 | - | $0.03 | $0.02 | $-0.01 | $-0.10 | $0.01 | $-0.07 | $-0.08 | $-0.19 | $-0.16 | $-0.04 | $0.03 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.47 | $0.01 | $0.31 | $0.31 | $0.47 | $0.43 |
| Low Forecast | $0.10 | $0.08 | $0.08 | $0.06 | $0.06 | $0.04 | $0.02 | $-0.00 | $0.02 | $0.02 | $-0.01 | $-0.11 | $0.01 | $-0.08 | $-0.08 | $-0.20 | $-0.17 | $-0.04 | $0.03 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.47 | $0.01 | $0.31 | $0.31 | $0.47 | $0.43 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.93% | 17.51% | 3.47% | 3.18% | 10.75% | -7.20% | 3.13% | 4.01% | -17.44% | 0.59% | 3.44% | 1.27% | -26.67% | -2.42% | -4.93% | -0.24% | -0.65% |
According to 5 Wall Street analysts, Myriad Genetics's projected average Quarter EPS for Dec 21 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -107.65% decrease compared to MYGN previous annual EPS of $0.31 (Sep 21).
Myriad Genetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | $3.14 | $14.00 | 345.86% | Buy |
| PSNL | Personalis | $3.59 | $7.75 | 115.88% | Hold |
| GH | Guardant Health | $28.96 | $57.27 | 97.76% | Buy |
| MYGN | Myriad Genetics | $15.22 | $29.00 | 90.54% | Hold |
| EXAS | Exact Sciences | $49.54 | $89.67 | 81.01% | Buy |
| ILMN | Illumina | $130.74 | $202.44 | 54.84% | Buy |
| CSTL | Castle Biosciences | $27.90 | $40.50 | 45.16% | Buy |
| CDNA | CareDx | $21.56 | $29.75 | 37.99% | Buy |
| MEDP | Medpace | $308.93 | $399.20 | 29.22% | Hold |
| QGEN | Qiagen | $40.99 | $51.89 | 26.59% | Buy |
| SHC | Sotera Health Company | $13.88 | $17.43 | 25.58% | Buy |
| NEOG | Neogen | $15.20 | $17.50 | 15.13% | Buy |
| TWST | Twist Bioscience | $41.43 | $42.40 | 2.34% | Buy |
| RDNT | RadNet | $79.09 | $69.00 | -12.76% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
| NTRA | Natera | $153.42 | $120.92 | -21.18% | Buy |